Abstract CT109: A Phase I dose escalation and expansion study of seclidemstat (SP-2577) a first-in class reversible LSD1 inhibitor for patients with relapsed or refractory Ewing sarcoma
Year: 2019
Type: conference-abstract
Source: Cancer Research
Institutions: Moffitt Cancer Center, Harvard University, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, The University of Texas MD Anderson Cancer Center, Children's Hospital Los Angeles, Johns Hopkins All Children's Hospital, Abigail Wexner Research Institute, The Ohio State University, Albert Einstein College of Medicine, University of Minnesota, University of Minnesota, Duluth
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2955289597